NCT03805711终止不适用
Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve CE Mark Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- HLT Inc.
- 入组人数
- 1
- 试验地点
- 2
- 主要终点
- All-cause mortality
研究概览
简要总结
To evaluate the safety and performance of the HLT System in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery.
详细描述
Prospective, non-randomized, single arm, multi-center CE Mark trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Echocardiographic or hemodynamic based evidence of severe aortic stenosis with one of the following:
- •Aortic valve area ≤ 1.0 cm^2 or 0.6 cm^2/m^2
- •Mean aortic valve gradient ≥ 40 mmHg
- •Peak aortic valve velocity ≥ 4 m/sec
- •Symptoms due to severe aortic stenosis resulting in one of the following:
- •NYHA Functional Classification of II or greater
- •Presence of angina
- •Presence of syncope
- •Documented aortic valve annular size of ≥ 24 and ≤ 26 mm (associated perimeter range is 76-81mm or associated area range of 453-530 mm2) by the MSCT Core Lab assessment of pre-procedure imaging.
- •Patient is considered intermediate or high risk to undergo surgical aortic valve replacement with one of the following:
- •Intermediate Surgical Risk: STS-PROM score of ≥ 3% to 8%
- •High Surgical Risk: STS-PROM score of ≥ 8%
- •Documented heart team agreement of risk for surgical aortic valve replacement (SAVR) due to other factors not captured by risk-scores (i.e. frailty or comorbidities)
- •Geographically available, willing to comply with follow up and able to provide written informed consent
排除标准
- •Patients with a coronary height of <10mm, or otherwise determined to be at high risk for coronary obstruction
- •Patients with low flow/low gradient aortic stenosis
- •Patients with significant annular or LVOT calcification that could compromise procedural success
- •Pre-existing prosthetic heart valve in any position, or prosthetic ring
- •Severe aortic, mitral or tricuspid valve regurgitation
- •Untreated clinically significant coronary artery disease requiring revascularization
- •Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification or severe tortuosity) that would preclude passage of 18 Fr catheters from the femoral arterial access to the aorta as evidenced by peripheral MSCT
- •Need for emergent surgery or intervention other than the investigational procedure
结局指标
主要结局
All-cause mortality
时间窗: 30 days
Freedom from all-cause mortality
次要结局
- Rate of Adverse Events(Throughout the 5-year follow-up period, assessed annually at a minimum)
- Post-procedural Valve Performance(14 Days (or earlier if discharged prior to post-op Day 14), 30 Days, 6 months, 12 months, 24 months, 36 months, 48 months and 60 months)
- Procedural Device Performance(During the Procedure)
研究者
研究点 (2)
Loading locations...
相似试验
终止
不适用
Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility TrialAortic Valve StenosisNCT02799823HLT Inc.11
已完成
不适用
Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Feasibility Trial CANADAAortic Valve StenosisNCT02838680HLT Inc.15
撤回
不适用
HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON CANADASevere Aortic StenosisNCT02159794HLT Inc.
已完成
不适用
HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiONSevere Aortic StenosisAortic Valve StenosisNCT02157142HLT Inc.4
Unknown
不适用
Heart Leaflet Technologies Valve StudyAortic Valve StenosisEndovascular Aortic Valve ReplacementNCT00710775Centro Cardiologico Monzino7